Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of LVRNA009 mRNA COVID-19 vaccine in adults aged 18-59 years in China
ChiCTR2200057782Phase 2Recruiting
- Sponsor
- Hunan Center for Disease Control and Prevention
- Start
- Mar 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LVRNA009 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Hunan Center for Disease Control and Prevention. Primary endpoints: Levels of SARS-CoV-2 S protein antibody (IgG) and Levels of SARS-CoV-2 neutralizing antibodies. Started Mar 2022; status: recruiting.
02
Drugs
LVRNA009
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200057782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057782.